Neoadjuvant TACE With or Without RT for HCC Involving PVTT
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus
(PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection.
However, 5-years recurrence rate is up to 75%. Some retrospective studies found transarterial
chemoembolization or radiotherapy can downstage HCC.